Clinical trial
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
NCT04772235
Study timeline
Study start (actual)2022-02-11Date precision: day
Registry last updated2024-04-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Nsclcunresolved
Interventions
RepotrectinibDRUG · verified · RxNorm: repotrectinib
OsimertinibDRUG · verified · RxNorm: osimertinib
Sponsors & collaborators
Instituto Oncológico Dr Roselllead sponsor
Turning Point Therapeutics, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04772235 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.